Immunohistochemical Investigation of BRAF p.V600E Mutations in Thyroid Carcinoma Using 2 Separate BRAF Antibodies

Abstract

The suboptimal specificity and PPV limits the diagnostic utility of both antibodies to reliably detect BRAF p.V600E mutations in thyroid carcinoma. However, both antibodies provide excellent sensitivity and NPV and either could be used to exclude BRAF wild-type thyroid carcinomas before molecular testing.